Trial Profile
Safety and Tolerability of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Extension Study to Study 3104001
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Orion
- 04 Jul 2022 Results of pooled analysis from NCT02363855, NCT01317641/NCT01429064, and NCT01784757, evaluating safety and tolerability of long-term treatment with darolutamide in patients, presented at the 37th Congress of the European Association of Urology
- 19 Feb 2022 Results of pooled analysis assessing long term safety by using data from three phase I/II studies presented at the 2022 Genitourinary Cancers Symposium
- 10 May 2016 Results of combined long-term safety and efficacy data from three studies including this study presented at the 111th Annual Meeting of the American Urological Association